EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

A novel dual NLRP1 and NLRP3 inflammasome inhibitor for the treatment of inflammatory diseases

Callum Ah Docherty, Anuruddika J Fernando, Sarah Rosli iD, Maggie Lam iD, Roland E Dolle, Manuel A Navia, Ronald Farquhar, Danny La France, Michelle D Tate iD, Christopher K Murphy, Adriano G Rossi iD, Ashley Mansell iD

Clinical & Translational Immunology · 2023-01 · 12 (6)

DOI: 10.1002/cti2.1455 ↗

At a glance

Journal article in Clinical & Translational Immunology, published online on 2023-06-22. Written by Callum Ah Docherty and 11 co-authors. Institution: Centre for Innate Immunity and Infectious Diseases Hudson Institute of Medical Research Clayton VIC Australia. Cited 47 times so far (Crossref); 62 references. The full text is freely available (open access, CC BY 4.0). Funded by: Medical Research Council, National Health and Medical Research Council.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Objectives

Inflammasomes induce maturation of the inflammatory cytokines IL‐1β and IL‐18, whose activity is associated with the pathophysiology of a wide range of infectious and inflammatory diseases. As validated therapeutic targets for the treatment of acute and chronic inflammatory diseases, there has been intense interest in developing small‐molecule inhibitors to target inflammasome activity and reduce disease‐associated inflammatory burden.

Methods

We examined the therapeutic potential of a novel small‐molecule inhibitor, and associated derivatives, termed ADS032 to target and reduce inflammasome‐mediated inflammation in vivo . In vitro , we characterised ADS032 function, target engagement and specificity.

Results

We describe ADS032 as the first dual NLRP1 and NLRP3 inhibitor. ADS032 is a rapid, reversible and stable inflammasome inhibitor that directly binds both NLRP1 and NLRP3, reducing secretion and maturation of IL‐1β in human‐derived macrophages and bronchial epithelial cells in response to the activation of NLPR1 and NLRP3. ADS032 also reduced NLRP3‐induced ASC speck formation, indicative of targeting inflammasome formation. In vivo , ADS032 reduced IL‐1β and TNF‐α levels in the serum of mice challenged i.p. with LPS and reduced pulmonary inflammation in an acute model of lung silicosis. Critically, ADS032 protected mice from lethal influenza A virus challenge, displayed increased survival and reduced pulmonary inflammation.

Conclusion

ADS032 is the first described dual inflammasome inhibitor and a potential therapeutic to treat both NLRP1‐ and NLRP3‐associated inflammatory diseases and also constitutes a novel tool that allows examination of the role of NLRP1 in human disease.

Subjects

Author keywords

NLRP1NLRP3drug targetsinflammasomeinflammationpulmonary inflammation

Authors and institutions

  • Centre for Innate Immunity and Infectious Diseases Hudson Institute of Medical Research Clayton VIC Australia.
  • Department of Molecular and Translational Sciences Monash University Clayton VIC Australia.
  • University of Edinburgh Centre for Inflammation Research Queen's Medical Research Institute, Edinburgh BioQuarter Edinburgh UK.
  • Department of Biochemistry and Molecular Biophysics Washington University School of Medicine St. Louis MO USA.
  • Hub-Bio Strategic Advising Lexington MA USA.
  • Adiso Therapeutics Concord MA USA.

ORCID profiles: Sarah Rosli, Maggie Lam, Michelle D Tate, Adriano G Rossi, Ashley Mansell

Funding

  • Medical Research Council
  • National Health and Medical Research Council

Cite

APA

Docherty, C. A., Fernando, A. J., Rosli, S., Lam, M., Dolle, R. E., Navia, M. A., Farquhar, R., La France, D., Tate, M. D., Murphy, C. K., Rossi, A. G., & Mansell, A. (2023). A novel dual NLRP1 and NLRP3 inflammasome inhibitor for the treatment of inflammatory diseases. Clinical & Translational Immunology, 12(6). https://doi.org/10.1002/cti2.1455

Vancouver

Docherty CA, Fernando AJ, Rosli S, Lam M, Dolle RE, Navia MA, et al. A novel dual NLRP1 and NLRP3 inflammasome inhibitor for the treatment of inflammatory diseases. Clinical & Translational Immunology. 2023;12(6). doi:10.1002/cti2.1455

BibTeX
@article{Docherty2023,
  author = {Docherty, Callum Ah and Fernando, Anuruddika J and Rosli, Sarah and Lam, Maggie and Dolle, Roland E and Navia, Manuel A and Farquhar, Ronald and La France, Danny and Tate, Michelle D and Murphy, Christopher K and Rossi, Adriano G and Mansell, Ashley},
  title = {A novel dual NLRP1 and NLRP3 inflammasome inhibitor for the treatment of inflammatory diseases},
  journal = {Clinical & Translational Immunology},
  year = {2023},
  volume = {12},
  number = {6},
  doi = {10.1002/cti2.1455}
}
Start for free →